Τόμος 21 (2003) – Τεύχος 2+2Σ – Άρθρο 9 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 21 (2003) – Issue 2+2Σ – Article 9 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Χάρις Καραγεωργίου¹, Απόστολος Ζάρρος¹, Κλεοπάτρα Σούλπη², Στυλιανός Τσακίρης³

¹ Εργαστήριο Πειραματικής Φαρμακολογίας, Ιατρική Σχολή Πανεπιστημίου Αθηνών, Αθήνα, Ελλάς ² Ινστιτούτο Υγείας του Παιδιού, Νοσοκομείο Παίδων Αγία Σοφία, Αθήνα, Ελλάς ³ Εργαστήριο Πειραματικής Φυσιολογίας, Ιατρική Σχολή Πανεπιστημίου Αθηνών, Αθήνα, Ελλάς

Haris Carageorgiou¹, Apostolos Zarros¹, Kleopatra Schulpi², Stylianos Tsakiris³

¹ Department of Experimental Pharmacology, Medical School, University of Athens, Athens, Greece ² Institute of Child Health, Aghia Sophia Chil­dren’s Hospital, Athens, Greece ³ Department of Experimental Physiology, Medi­cal School, University of Athens, Athens, Greece

2. Parkinson Study Group: Effect of tocopherol and (-)de­prenyl to the progression of disability in early Parkinson’s disease. N. Eng. J. Med. 328: 176-83 (1993)

3. Negrotti A., Bizzarri G., Calzetti S.: Long-term persis­tence of symptomatic effect of selegiline in Parkinson’s disease. A two-months placebo-controlled withdrawal study. J. Neural. Transm. 108: 215-9 (2001)

4. Mendlewicz J., Youdim M.B.H.: L-Deprenyl, a selective monoamine oxidase type B inhibitor in the treatment of depression, a double-blind evaluation. Br. J. Psychiatry 142: 508-11 (1983)

5. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cot­man C.W., Pfeiffer E., Schneider L.S., Thal L.J.: A con­trolled trial of selegiline, alpha-tocopherol, or both as treat­ment for Alzheimer’s disease. N. Engl. J. Med. 336: 1216-22 (1997)

6. Luxenberg J.S.: Review: selegiline leads to a small short term improvement in cognition and activities of daily living in Alzheimer’s disease. Evid. Based. Ment. Health 5: 88 (2002)

7. Lange W.K., Riederer P., Youdim M.: Biochemical ac­tions of L-deprenyl (selegiline). Clin. Pharmacol. Ther. 56: 734-741 (1994)

8. Ebadi M., Sharma S., Shavali S., Refaey E.H.: Neuro­protective action of selegiline. J. Neurosci. Res. 67: 285-289 (2002)

9. Langston S.W., Tannen C.M.: Selegiline and Parkinson’s disease: it’s déjà vu-again. Neurology 55:1770-1 (2000)

10. Magyar K., Haberle D.: Neuroprotective and neuronal rescue effects of selegiline. Neurobiology 7: 175-90 (1999)

11. Matsubara K., Senda T., Uezono T., Awaya T., Ogawa S., Chiba K., Shimizu K., Hayase N., Kimura K.: L-deprenyl prevents the cell hypoxia induced by dopaminergic neuro­toxins, MPP⁺, and β-carbolinium: a microdialysis study in rats. Neurosci. Lett. 302: 65-8 (2001)

12. Ricci A., Mancinin M., Strocchi P., Bongrani S., Bron­zetti E.: Deficits in cholinergic aziridium (AF64A) in rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp. Clin. Res. 18: 163-71 (1992)

13. Dalló J.: Effect of chronic (-)deprenyl treatment on life­span and copulatory activity in female rats. Fundam. Clin. Pharmacol. 13(Suppl1): 148s PS96 (1999)

14. Carillo M.C., Kitani K., Kanai S., Sato Y., Miyasaka K., Ivy G.O.: (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci. 54: 975-81 (1994)

15. Cohen G., Spina M.B.: (-)Deprenyl suppresses the oxidant stress associated with increased dopamine turn­over. Ann. Neurol. 26: 689-90 (1981)

16. Ju W.Y.H., Holland D.P., Tatton W.G.: (-)Deprenyl alters the time course of death of axotomised facial moto­neurons and the hypertrophy of neighbouring astrocytes in immature rats. Exp. Neurol. 126: 233-46 (1994)

17. Lakshmana K.M., Shankaranarayana Rao S.B., Dhin­gra K.N., Ravikumar R., Govindaiah, Ramachandra, Meti B.L., Raju R.T.: Chronic (-)deprenyl administration in­creases dendritic arborization in CA3 neurons of hippo­campus and AChE activity in specific regions of the primate brain. Brain Res. 796: 38-44 (1998)

18. Knoll J.: The pharmacology of selegiline ((-) deprenyl). New aspects. Scand. Suppl. 126: 83-91 (1989)

19. Καραγεωργίου Χ.: Νόσος Alzheimer το 2000, σύγχρονες απόψεις για τη φυσιοπαθολογία και τις φαρμακευτικές προσεγγίσεις της νόσου. Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής 17(2): 53-96 (1999)

20. Antoniades C., Carageorgiou H., Tsakiris S.: Effects of (-)deprenyl (selegiline) on acetylcholinesterase and Na⁺,K⁺-ATPase activities in adult rat whole brain. Pharmacol. Res. 46: 165-9 (2002)

21. Committee on Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. Wash­ington D.C.: Institute of Laboratory Animal Resources, National Research Council, 1985: 83

22. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J.: Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-75 (1951)

23. Ellman G.L., Courtney D., Andres D., Featherstone R.M.: A new and rapid colorimetric determination of acetyl­cholinesterase activity. Biochem. Pharmacol. 7: 88-95 (1961)

24. Tsakiris S., Antoniades C., Marinou K.: Pseudocholi­nesterase activity distribution in rat brain: detection in aged hypothalamus and frontal cortex. Med. Sci. Res. 28: 117-8 (2000)

25. Dews P.B., Morse W.H.: Behavioral Pharmacology. Ann. Rev. Pharmacol. 1: 145-74 (1961)

26. Zhu J., Hamm R.J., Reeves T.M., Povlishock J.T., Phillips L.L.: Post injury administration of L-deprenyl im­proves cognitive function and enhances neuroplasticity after traumatic brain injury. Exp. Neurol. 166: 136-52 (2000)

27. Fishman E.B., Siek G.C., MacCallum R.D., Bird E.D., Volicer L., Marqui J.K.: Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in de­mentia of the Alzheimer type. Ann. Neurol. 19: 246-52 (1986)

28. Dekosky S.T., Harbaugh R.E., Schmitt F.A., Bakay R.A., Chui H.C., Knopman D.S., Reeder T.M., Shetter A.G., Senter H.J., Markesbery W.R.: Cortical biopsy in Alz­heimer’s disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraven­tricular Bethanecol Study Group. Ann. Neurol. 32: 625-32 (1992)

29. Appleyard M.E.: Acetylcholinesterase induced long-term potentiation in CA1 pyramidal cells by a mechanism dependent on metabotropic glutamate receptors. Neurosci. Lett. 190: 25-8 (1995)

30. Shen Z.X.: The significance of the activity of CSF choli­nesterases in dementias. Med. Hypotheses 47: 363-76 (1996)

31. Reynolds G.P., Riederer P., Sandler M., Jellinger K., Seeman D.: Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration. J. Neural Transm. 43: 271-7 (1978)

32. Carageorgiou H., Zarros A., Tsakiris S.: Selegiline long-term effects on brain acetylcholinesterase, (Na⁺,K⁺)-ATPase activities, antioxidant status and learning perform­ance of aged rats. Pharmacol. Res. Article in press (2003)